Poster Abstracts • OFID 2019:6 (Suppl 2) • S525 1,111/1,678 (66%) patients were asymptomatic when MSU was ordered. 1,393/1,678 (83%) had negative culture (N = 482) or completed d4 follow-up (N = 911). No symptomatic UTI/sepsis/systemic infection occurred; the only AE identified were 4 patients with prolonged UTS which might have been prevented by MSU processing (4/911; 0.4% patients with AE). Rates of MSU submitted remained stable at 12 per 1,000 patient-days, P = 0.59 ( Figure 1 ). Proportion of processed MSU decreased from 16/22, 73% in 2013 to 67/137, 49% in 2019 ( Figure 2 ; P = 0.002). Overall, microbiology workload decreased by 5 person-days/year (fewer MSU processed, but staff needed to respond to telephone calls). 275/1,678 (16%) patients received AB for presumed UTI; 221 (80%) treated empirically, 54 (20%) in response to positive MSU. Of 69 patients with ASB whose MSU was processed and positive, 32 (46%) were prescribed antibiotics. Assuming that 21% of rejected MSU from asymptomatic patients would have been positive, AB therapy for ASB was avoided in 66 patients.
Background. EC sequence type ST131 is the leading cause of extraintestinal EC infections, and accounts for most fluoroquinolone (FQ)-resistant and extended-spectrum β-lactamase (ESBL)-producing EC clinical isolates. The ST131-H30 subclone (H30) is responsible for most antimicrobial resistance within ST131; however, H30's impact on clinical outcomes is poorly defined. We compared empiric treatment patterns and clinical outcomes of patients with bacteriuria caused by ST131 vs. non-ST131 EC, and by H30 vs. non-H30 EC strains.
Methods. Phylogroups, ST131, H30, and CTX-M-type β-lactamase genes were detected by PCR for 142 non-duplicate EC isolates collected prospectively from hospitalized or emergency-department-attending adults with monomicrobial bacteriuria at a Boston academic medical center (August 2013-January 2014). Clinical and microbiologic data were collected retrospectively from electronic health records. Baseline characteristics, empiric treatment, and clinical cure rates were compared between ST131 vs. non-ST131, and H30 vs. non-H30, patient cohorts.
Results.
Of 142 patients with EC bacteriuria, most (76%) were female and elderly (mean age 65.2 ± 21.2 years). Overall, 35% of isolates were ST131, of which 80% (39/49) were H30. Compared with other isolates, H30 isolates demonstrated a higher frequency of ESBL production (33% vs. 8%; P < 0.001) and FQ resistance (90% vs. 8%; P > 0.001). Patients with H30 isolates (vs. non-H30 isolates) were older (mean 73.4 ± 13.6 vs. 62.1 ± 22.7 years; P < 0.01), had higher median (interquartile range [IQR]) APACHE II scores (10 [4] vs. 8 [9.5] ; P = 0.01), more commonly had underlying complicating conditions (100% vs. 83%; P = 0.03) and received in vitro-inactive empirical treatment (26% vs. 3%; P < 0.01), and had a numerically lower clinical cure rate (84% vs. 96%; P = 0.08). In contrast, patients with ST131 vs. non-ST131 isolates had similar median [IQR] APACHE II scores (9 [5] vs. 8 [9]), frequencies of symptomatic UTI (61% vs. 70%) and underlying complicating conditions (24% vs. 19%), and clinical cure rates (87% vs. 95%).
Conclusion. Among patients with EC bacteriuria, the ST131-H30 subclone was associated significantly with ESBL production, FQ resistance, illness severity, host compromise, and numerically lower clinical cure rates in symptomatic UTI.
Disclosures: Elizabeth B. Hirsch, PharmD, Merck: Grant/Research Support, Research Grant; Nabriva Therapeutics: Advisory Board; Paratek Pharmaceuticals: Advisory Board. Background. Almost half of urine cultures (UCs) obtained are in asymptomatic patients, which may lead to misdiagnosis of urinary tract infection (UTI) and unnecessary treatment. To decrease misdiagnosis of UTI, changes were made to the order entry and urine culture process at our institution in April 2018. This included removal of a standalone UC from the electronic order entry system and development of a more stringent criterian for urinalysis with reflex culture (UAC). We evaluated the impact of these ordering changes on the total number of UCs performed.
Reducing the Number of Urine Cultures Performed Through Stringent Urinalysis Reflex Criteria
Methods. This was a pre-post retrospective study comparing the hospital UAC rate per 1,000 patient-days and ED UAC rate per 1,000 visits in the pre-intervention period from April 2017 to March 2018 to the intervention period from May 2018 to March 2019 in a 319-bed teaching hospital in northwest Ohio. In April 2018, urine microscopy and UAC were the only available options. Furthermore, UC would only be performed if the following criteria were met: 10 white blood cells (WBC)/HFP. Standalone UC was available for the following patients who were excluded: immunosuppressed patients, pregnant women and patients undergoing invasive urologic procedures. These changes were accompanied by provider education, and providers were given the option to override UAC rules by calling the microbiology lab within 24 hours to request UC.
Results. After incorporating these changes, we observed an increase in the use of UAC compared with UC-only in both the ED (80% pre-vs. 94% post-implementation) and inpatient setting (59% pre-vs. 92% post-implementation). This was accompanied by a reduction in the overall UCs performed in both the ED (49.17 per 1,000 visits to 23.53 per 1,000 visits [P < 0.001]) and inpatient units (23.31 per 1,000 patient-days to 9.31 per 1,000 patient-days [P < 0.001]). Chart review of cases where providers overrode UAC criteria and requested UC have demonstrated no false negatives to date; cultures either had no growth or were consistent with contamination by polymicrobial urogenital flora.
Conclusion.
Restricted access to standalone UC, implementation of UAC with more stringent criteria and provider education reduced the number of urine cultures performed without sacrificing sensitivity for detecting UTI and potential antimicrobial use.
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Research Database, Becton, Dickinson & Company). ESBL was defined as an ENT that was ESBL-positive per commercial panels or intermediate or resistant (non-susceptible, [NS]) to a third-generation cephalosporin; CRE was defined as an ENT that was NS to imipenem, meropenem, doripenem or ertapenem. Urine isolates were classified as community-onset (CO: < 3 days of an inpatient admission and no previous admission within 14 days) or hospital-onset (HO: ≥ 3 days post-admission or within 14 days of discharge) period. Prevalence and rates per 100 admissions were calculated overall, by onset location (CO vs. HO), and by US Department of Health and Human Services (HHS) geographic region. Results. In 2018, there were 193,476 non-duplicate ENT urine isolates across 4,623,333 admissions; 63.6% were E. coli (EC), 19.5% were K. pneumoniae/oxytoca (KPO), and 8.7% were P. mirabilis (PM). Overall, 12.6% were ESBL and 0.9% were CRE. Rate per 100 admissions was 0.484 and 0.037 for ESBL and CRE, respectively. Among CO, 11.8% were ESBLs and ESBL rates per 100 admissions were 0.358; 0.7% were CRE and CRE rates per 100 admissions was 0.024. Among HO, 15.7% were ESBLs and ESBL rates per 100 admissions was 0.126; 1.5% were CRE and CRE rates per 100 admissions was 0.013. Regional differences in both ESBL and CRE ENT were noted (table) .
Conclusion. The prevalence of ESBLs/CRE among adult hospitalized patients with ENT in a urine culture was 13% and 1%, respectively. The % ESBL/CRE was higher among patients HO urine isolates whereas ESBL/CRE rates per 100 admissions were higher among patients with CO urine isolates. Considerable geographic variations were observed. Region and site of onset differences in ESBL/CRE epidemiology should be considered when making empiric antibiotic treatment decisions.
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Comparison of Cefpodoxime vs. Oral Cefuroxime for Urinary Tract Infections at a Large Academic Medical Center
Hongkai Bao, PharmD 1 ; Yanina Dubrovskaya, PharmD 2 ; Shin-Pung (Polly) Jen, PharmD, BCPS-AQ ID, AAHIVP 1 ; Xian Jie (Cindy) Chen, PharmD, BCPS 1 ; Justin Siegfried, PharmD, BCPS 1 ; John Papadopoulos, BS, PharmD, FCCM, BCCCP, BCNSP 1 ; 1 New York University Langone Health, New York, New York; 2 New York University, New York City, New York Friday, October 4, 2019: 12:15 PM Background. Cefpodoxime (CPD) and cefuroxime (CFX) are both oral cephalosporins indicated for urinary tract infection (UTI) treatment. CPD may have unfavorable pharmacokinetics (PK) given the lesser degree of renal excretion and urine concentration vs. CFX and risk of collateral damage. The objective of this study was to compare the efficacy and safety of these two agents for UTI treatment.
Session: 157. Urinary Tract Infections
Methods. We conducted a retrospective evaluation among adult patients who received CPD or oral CFX for ≥48 hours for UTI treatment between January 2013 and July 2018. The primary outcome was the rate of subsequent UTI within 90 days following therapy. Safety outcomes included the rate of Clostridium difficile infection (CDI) and development of isolates resistant to third-generation cephalosporins (TGC) within 90 days. We also examined missed opportunities for antibiotic de-escalation in culture-positive patients.
Results. Of 747 patients assessed for study inclusion, 295 patients met eligibility criteria (CPD n = 165, CFX n = 130). Median age was 72 years (IQR 55-84) and 71% were female. More patients in the CPD vs. CFX group had pyelonephritis (29% vs. 11%, P = 0.0005) and were treated in the emergency department (42% vs. 16%, P = 0.0005). Escherichia coli was most commonly isolated (n = 139), followed by Klebsiella spp. The rate of subsequent UTI for CPD vs. CFX was 18% vs. 16%, P = 0.647 at median of 25 vs. 32 days, P = 0.399. CDI rate was 1% vs. 2%, P = 0.324 and resistance to TGC was detected in 4% vs. 1%, P = 0.068 for CPD vs. CFX, respectively. Missed opportunities to de-escalate antibiotics based on cultures were found in one-third of patients. After adjusting for multiple factors in multivariate analysis, genitourinary abnormality (Odds Ratio [OR] 2.2, 95% CI 1.10-4.29, P = 0.026) and prior history of UTI within 180 days (OR 2.2, 95% CI 1.08-4.398, P = 0.03), but not the choice of oral cephalosporin, were the only independent predictors of subsequent UTI.
Conclusion. Despite less favorable urinary PK of CPD compared with CFX, in this patient cohort, no differences in efficacy or safety between the two agents for UTI treatment were found. These findings warrant further exploration. Stewardship strategies for de-escalation from higher generation cephalosporins to narrow-spectrum antibiotics based on susceptibilities should be implemented.
